TickerFacts.

BridgeBio Oncology Therapeutics, Inc. (BBOT): Cash & Equivalents

Annual figures by period end, from SEC filings.

$373.69M
As of 2025-12-31
$54.06M
As of 2026-06-30
2024-12-31: $30.85M2025-12-31: $373.69M$373.69M
2024-12-31 Cash & Equivalents (USD) 2025-12-31
Period endedCash & EquivalentsChange YoYSource filing
2025-12-31$373.69Mn/m2026-03-05, Balance as of period end
2024-12-31$30.85Mn/a2026-03-05, Balance as of period end

Cash & Equivalents at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCash & EquivalentsChange YoY
BridgeBio Oncology Therapeutics, Inc. (BBOT)2025-12-31$373.69Mn/m
Biohaven Ltd. (BHVN)2025-12-31$229.96M+132.0%
BGM Group Ltd. (BGM)2025-09-30$9.82M0.0%
Arcutis Biotherapeutics, Inc. (ARQT)2025-12-31$42.91M-39.9%
Bicara Therapeutics Inc. (BCAX)2025-12-31$96.69M-80.3%
MoonLake Immunotherapeutics (MLTX)2025-12-31$334.52M+85.4%
Enliven Therapeutics, Inc. (ELVN)2025-12-31$98.90M-20.3%
MapLight Therapeutics, Inc. (MPLT)2025-12-31$46.73M+22.2%
Rhythm Pharmaceuticals, Inc. (RYTM)2025-12-31$54.30M-39.1%

Compare BBOT, BHVN, BGM, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗